Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men

Sexual Health

Volumn 12, Issue 3, 2015, Pages 240-248

  Price, Julia ^a,b   Hoy, Jennifer ^b   Ridley, Emma ^a,b   Nyulasi, Ibolya ^a,b   Paul, Eldho ^b   Woolley, Ian ^b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; CHOLESTEROL; DIDANOSINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SAQUINAVIR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; TRIACYLGLYCEROL; ZIDOVUDINE;

ABDOMINAL FAT; ADULT; ARTICLE; BODY FAT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT MASS; HIP CIRCUMFERENCE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

EID: 84931080285     PISSN: 14485028     EISSN: 14498987     Source Type: Journal    
DOI: 10.1071/SH14084     Document Type: Article

References (33)

1. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338: a3172. doi:10.1136/bmj.a3172
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-8. doi:10.1097/00002030-199807000-00003
3. Bisson G, Gross R, Miller V, et al. Monitoring of long-term toxicities of HIV treatments: an international perspective. AIDS 2003; 17: 2407-17. doi:10.1097/00002030-200311210-00002
4. Murray JM, McDonald AM, Law MG. Rapidly ageing HIV epidemic among men who have sex with men in Australia. Sex Health 2009; 6: 83-6. doi:10.1071/SH08063
5. Orlando G, Meraviglia P, Cordier L, et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med 2006; 7: 549-57. doi:10.1111/j.1468-1293.2006.00420.x
6. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003; 4: 293-301. doi:10.1046/j.1468-1293.2003.00159.x
7. Jerico C, Knobel H, Montero M, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 2005; 28: 132-7. doi:10.2337/diacare.28.1.132
8. Worm SW, Sabin CA, Reiss P, et al. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care 2009; 32: 474-80. doi:10.2337/dc08-1394
9. Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21: 2445-53. doi:10.1097/QAD.0b013e3282efad32
10. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-32. doi:10.1016/j.jacc.2010.05.034
11. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361: 726-35. doi:10.1016/S0140-6736(03)12656-6
12. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-67. doi:10.1097/00002030-199909100-00009
13. AHO Database. The Australian HIV observational database. Available at: http://hiv.cms.med.unsw.edu.au/ [verified 14 February 2011].
14. Guaraldi G, Baraboutis IG. Evolving perspectives on HIV-associated lipodystrophy syndrome: moving from lipodystrophy to noninfectious HIV co-morbidities. J Antimicrob Chemother 2009; 64: 437-40. doi:10.1093/jac/dkp240
15. Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I, Mijch AM. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med 2001; 2: 174-80. doi:10.1046/j.1468-1293.2001.00073.x
16. Gibson R. Principles of nutritional assessment. New York: Oxford University Press; 1990.
17. Bonnet E, Delpierre C, Sommet A, et al. Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: proposal of reference values for defining lipodystrophy. J Clin Densitom 2005; 8: 287-92. doi:10.1385/JCD:8:3:287
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-2497. doi:10.1001/jama.285.19.2486
19. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47. doi:10.1161/01.CIR.97.18.1837
20. Nguyen A, Calmy A, Schiffer V, et al. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Med 2008; 9: 142-50. doi:10.1111/j.1468-1293.2007.00537.x
21. Baumgartner RN, Heymsfield SB, Roche AF. Human body composition and the epidemiology of chronic disease. Obes Res 1995; 3: 73-95. doi:10.1002/j.1550-8528.1995.tb00124.x
22. Harris TB. Invited commentary: body composition in studies of aging: new opportunities to better understand health risks associated with weight. Am J Epidemiol 2002; 156: 122-6. doi:10.1093/aje/kwf024
23. Gallagher D, Ruts E, Visser M, et al. Weight stability masks sarcopenia in elderly men and women. Am J Physiol Endocrinol Metab 2000; 279: E366-75.
24. Brown TT, Chu H, Wang Z, et al. Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy. AIDS 2007; 21: 1731-8. doi:10.1097/QAD.0b013e328270356a
25. Ribera E, Paradineiro JC, Curran A, et al. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). HIV Clin Trials 2008; 9: 407-17. doi:10.1310/hct0906-407
26. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18: 1029-36. doi:10.1097/00002030-200404300-00011
27. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38: 263-70. doi:10.1086/380790
28. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. J. Am. Med. Assoc. 2002; 288: 207-15. doi:10.1001/jama.288.2.207
29. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [verified February 2011].
30. EAC Society. Clinical management and treatment of HIV-infected adults in Europe Guidelines. Available at: http://www.europeanaidsclinicalsociety.org/index.php?option=com-content&view=article&id=59&Itemid=41 [verified February 2011].
31. Petoumenos K, Worm S, Reiss P, et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study. HIV Med 2011; 12: 412-21. doi:10.1111/j.1468-1293.2010.00901.x
32. Worm SW, Friis-Moller N, Bruyand M, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010; 24: 427-35. doi:10.1097/QAD.0b013e328334344e
33. Barr L, Magliano D, Zimmet P, et al. AusDiab 2005. The Australian Diabetes, Obesity and Lifestyle Study. Tracking the accelerating epidemic: its causes and outcomes. Melbourne: International Diabetes Institute; 2006.